Company research
PepGen Inc.
CIK 1835597Updated Nov 13, 2026
SecurityPEPG · NASDAQ · equity
PEPG price & chart
Loading TradingView…
NASDAQ:PEPG on TradingView ↗About the company
PepGen Inc. is a clinical-stage biotechnology company pioneering oligonucleotide therapies with the potential to transform the treatment of rare genetic diseases. Founded on more than a decade of research and development, PepGen’s Enhanced Delivery Oligonucleotide (EDO) technology leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using this EDO technology, PepGen is advancing PGN-EDODM1, a clinical candidate for the treatment of myotonic dystrophy type 1.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG ↗
PepGen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 8, 2025 to Discuss Your Rights - PEPG News provided by Levi & Korsinsky, LLP Aug 08, 2025, 08:45 ET Share this article Share to X Share this article Share to X NEW YORK , Aug. 8, 2025 /PRNewswire/ -- Le ↗
Recent filings
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
424B5 filing
424B5 filing
Results of Operations and Financial Condition · Regulation FD Disclosure · Other Events
Items 2.02, 7.01, 8.01, 9.01
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 190,057,000Source | 170,234,000Source | 141,397,000Source | 102,242,000Source | 193,510,000Source | 156,295,000Source | 127,393,000Source | 207,000,000Source | 173,907,000Source | 150,883,000Source | 143,052,000Source | 217,440,000Source |
| Property, Plant and Equipment, NetUSD | 2,220,000Source | 3,901,000Source | 1,341,000Source | 2,489,000Source | 4,236,000Source | 1,565,000Source | 3,506,000Source | 4,440,000Source | 1,903,000Source | 3,716,000Source | 4,764,000Source | 3,335,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 142,775,000Source | 42,289,000Source | 22,764,000Source | 35,072,000Source | 66,085,000Source | 42,150,000Source | 43,633,000Source | 133,854,000Source | 60,514,000Source | 49,421,000Source | 80,774,000Source | 181,752,000Source |
| Assets, CurrentUSD | 166,206,000Source | 142,369,000Source | 120,329,000Source | 77,486,000Source | 164,778,000Source | 134,271,000Source | 101,047,000Source | 177,619,000Source | 150,963,000Source | 123,761,000Source | 112,678,000Source | 186,083,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,541,000Source | 3,512,000Source | 3,091,000Source | 2,833,000Source | 3,472,000Source | 1,968,000Source | 3,266,000Source | 2,396,000Source | 2,507,000Source | 3,570,000Source | 2,271,000Source | 4,273,000Source |
| Operating Lease, Right-of-Use AssetUSD | 19,711,000Source | 21,990,000Source | 17,914,000Source | 20,293,000Source | 22,540,000Source | 18,522,000Source | 20,866,000Source | 23,083,000Source | 19,121,000Source | 21,432,000Source | 23,620,000Source | 26,549,000Source |
| Other Assets, NoncurrentUSD | 372,000Source | 426,000Source | 265,000Source | 426,000Source | 1,956,000Source | 389,000Source | 426,000Source | 1,858,000Source | 372,000Source | 426,000Source | 1,990,000Source | 1,473,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 26,917,000Source | 32,779,000Source | 21,864,000Source | 31,084,000Source | 38,470,000Source | 22,315,000Source | 35,588,000Source | 28,001,000Source | 26,463,000Source | 32,263,000Source | 34,631,000Source | 37,809,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 7,000Source | 3,000Source | 7,000Source | 3,000Source | 3,000Source | 7,000Source | 3,000Source | 3,000Source | 7,000Source | 3,000Source | 2,000Source | 2,000Source |
| Retained Earnings (Accumulated Deficit)USD | -342,778,000Source | -249,221,000Source | -396,693,000Source | -324,752,000Source | -227,837,000Source | -378,881,000Source | -301,665,000Source | -199,502,000Source | -361,118,000Source | -271,463,000Source | -181,482,000Source | -102,856,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -25,000Source | 91,000Source | -117,000Source | -43,000Source | -75,000Source | -59,000Source | -22,000Source | -37,000Source | 11,000Source | 23,000Source | 34,000Source | -81,000Source |
| Stockholders' Equity Attributable to ParentUSD | 163,140,000Source | 137,455,000Source | 119,533,000Source | 71,158,000Source | 155,040,000Source | 133,980,000Source | 91,805,000Source | 178,999,000Source | 147,444,000Source | 118,620,000Source | 108,421,000Source | 179,631,000Source |
| Additional Paid in Capital, Common StockUSD | 505,936,000Source | 386,582,000Source | 516,336,000Source | 395,950,000Source | 382,949,000Source | 512,913,000Source | 393,489,000Source | 378,535,000Source | 508,544,000Source | 390,057,000Source | 289,867,000Source | 282,566,000Source |
| Liabilities and EquityUSD | 190,057,000Source | 170,234,000Source | 141,397,000Source | 102,242,000Source | 193,510,000Source | 156,295,000Source | 127,393,000Source | 207,000,000Source | 173,907,000Source | 150,883,000Source | 143,052,000Source | 217,440,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 12,642,000Source | 16,810,000Source | 9,005,000Source | 16,360,000Source | 22,107,000Source | 8,964,000Source | 20,431,000Source | 11,258,000Source | 12,646,000Source | 16,696,000Source | 17,531,000Source | 18,828,000Source |
| Operating Lease, Liability, CurrentUSD | 3,163,000Source | 3,071,000Source | 3,234,000Source | 3,140,000Source | 3,049,000Source | 3,210,000Source | 3,117,000Source | 3,026,000Source | 3,187,000Source | 3,094,000Source | 3,004,000Source | 5,553,000Source |
| Accounts Payable, CurrentUSD | 766,000Source | 5,930,000Source | 1,095,000Source | 856,000Source | 7,741,000Source | 622,000Source | 2,699,000Source | 1,480,000Source | 822,000Source | 1,752,000Source | 1,005,000Source | 1,362,000Source |
| Operating Lease, Liability, NoncurrentUSD | 14,275,000Source | 15,969,000Source | 12,859,000Source | 14,724,000Source | 16,363,000Source | 13,351,000Source | 15,157,000Source | 16,743,000Source | 13,817,000Source | 15,567,000Source | 17,100,000Source | 18,981,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 8,713,000Source | 7,809,000Source | 4,676,000Source | 12,364,000Source | 11,317,000Source | 5,132,000Source | 14,615,000Source | 6,752,000Source | 8,637,000Source | 11,850,000Source | 13,522,000Source | 11,913,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 163,700,000Source | 138,900,000Source | 117,200,000Source | 74,700,000Source | 161,300,000Source | 132,300,000Source | 97,800,000Source | 175,200,000Source | 148,500,000Source | 120,200,000Source | 110,400,000Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 300,000Source | 400,000Source | 300,000Source | 300,000Source | 300,000Source | 400,000Source | 1,400,000Source | 1,500,000Source | 1,200,000Source | 500,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,855,000Source | 3,432,000Source | 10,609,000Source | 11,457,000Source | 7,048,000Source | 4,763,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -18,426,000Source | -22,930,000Source | -81,635,000Source | -82,372,000Source | -68,997,000Source | -59,265,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -1,459,000Source | 17,149,000Source | -15,235,000Source | -37,668,000Source | -32,003,000Source | -3,755,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 125,000Source | 264,000Source | 497,000Source | 2,599,000Source | 3,755,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 1,518,000Source | 0Source | 107,979,000Source | 88,749,000Source | -189,000Source | 112,193,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -18,364,000Source | -5,788,000Source | 11,093,000Source | -31,353,000Source | -100,903,000Source | 48,857,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 0Source | 86,000Source | 82,000Source | 71,000Source | 2,702,000Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,377,000Source | 3,226,000Source | 3,313,000Source | 2,363,000Source | 2,855,000Source | 3,432,000Source | 10,609,000Source | 11,457,000Source | 7,048,000Source | 4,763,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 163,700,000Source | 138,900,000Source | 117,200,000Source | 74,700,000Source | 132,300,000Source | 97,800,000Source | 148,500,000Source | 120,200,000Source | 110,400,000Source | — |
| DepreciationUSD | — | — | — | — | — | — | 319,000Source | 388,000Source | 1,397,000Source | 1,505,000Source | 1,184,000Source | 493,000Source |
| General and Administrative ExpenseUSD | — | — | 5,231,000Source | 5,449,000Source | 6,417,000Source | 5,541,000Source | 5,938,000Source | 5,943,000Source | 22,569,000Source | 21,261,000Source | 16,640,000Source | 14,224,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 16,000Source | 0Source | 15,000Source | 0Source | 48,865Source | -617,000Source | 73,000Source | 3,706,000Source |
| Investment Income, InterestUSD | — | — | 634,000Source | 1,826,000Source | 1,093,000Source | 842,000Source | 1,250,000Source | 1,122,000Source | 4,017,000Source | 7,142,000Source | 6,400,000Source | 2,793,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,026,000Source | -21,384,000Source | -17,812,000Source | -23,087,000Source | -17,763,000Source | -30,202,000Source | -89,655,000Source | -89,981,000Source | -78,626,000Source | -69,104,000Source |
| Noncash Merger Related CostsUSD | — | — | — | — | — | — | 0Source | 11,000Source | — | 70,000Source | — | 134,000Source |
| Nonoperating Income (Expense)USD | — | — | 628,000Source | 1,787,000Source | 1,143,000Source | 845,000Source | 1,194,000Source | 1,119,000Source | 4,006,000Source | 7,141,000Source | 6,213,000Source | 2,903,000Source |
| Operating ExpensesUSD | — | — | 18,654,000Source | 23,171,000Source | 18,939,000Source | 23,932,000Source | 18,942,000Source | 31,321,000Source | 93,612,000Source | 97,739,000Source | 84,766,000Source | 68,301,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -6,000Source | -39,000Source | 50,000Source | 3,000Source | -56,000Source | -3,000Source | -11,000Source | -1,000Source | -187,000Source | 110,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 1,511,000Source | 0Source | — | 9,900,000Source | — | 114,267,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 27,000,000Source | 24,000,000Source | 79,000,000Source | 108,000,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | — | 217,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -18,654,000Source | -23,171,000Source | -18,939,000Source | -23,932,000Source | -18,942,000Source | -31,321,000Source | -93,612,000Source | -97,739,000Source | -84,766,000Source | -68,301,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -6,000Source | -39,000Source | 50,000Source | 3,000Source | -56,000Source | -3,000Source | -11,000Source | -1,000Source | -187,000Source | 110,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -18,026,000Source | -21,384,000Source | -17,796,000Source | -23,087,000Source | -17,748,000Source | -30,202,000Source | -89,606,000Source | -90,598,000Source | -78,553,000Source | -65,398,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 16,000Source | 0Source | 15,000Source | 0Source | 48,865Source | -617,000Source | 73,000Source | 3,706,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,026,000Source | -21,384,000Source | -17,812,000Source | -23,087,000Source | -17,763,000Source | -30,202,000Source | -89,655,000Source | -89,981,000Source | -78,626,000Source | -69,104,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.52Source | -0.66Source | -0.26Source | -0.7Source | -0.26Source | -0.92Source | -2.12Source | -2.85Source | -3.3Source | -4.42Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.52Source | -0.66Source | -0.26Source | -0.7Source | -0.26Source | -0.92Source | -2.12Source | -2.85Source | -3.3Source | -4.42Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 34,362,876Source | 32,581,542Source | 69,202,376Source | 32,748,646Source | 69,091,100Source | 32,674,720Source | 42,221,808Source | 31,583,073Source | 23,796,000Source | 15,639,728Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 34,362,876Source | 32,581,542Source | 69,202,376Source | 32,748,646Source | 69,091,100Source | 32,674,720Source | 42,221,808Source | 31,583,073Source | 23,796,000Source | 15,639,728Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 49,000Source | -617,000Source | 73,000Source | 3,706,000Source |
| General and Administrative ExpenseUSD | — | — | 5,231,000Source | 5,449,000Source | 6,417,000Source | 5,541,000Source | 5,938,000Source | 5,943,000Source | 22,569,000Source | 21,261,000Source | 16,640,000Source | 14,224,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -89,606,000Source | -87,466,000Source | -78,195,000Source | -96,781,000Source |
| Investment Income, InterestUSD | — | — | 634,000Source | 1,826,000Source | 1,093,000Source | 842,000Source | 1,250,000Source | 1,122,000Source | 4,017,000Source | 7,142,000Source | 6,400,000Source | 2,793,000Source |
| Nonoperating Income (Expense)USD | — | — | 628,000Source | 1,787,000Source | 1,143,000Source | 845,000Source | 1,194,000Source | 1,119,000Source | 4,006,000Source | 7,141,000Source | 6,213,000Source | 2,903,000Source |
| Operating ExpensesUSD | — | — | 18,654,000Source | 23,171,000Source | 18,939,000Source | 23,932,000Source | 18,942,000Source | 31,321,000Source | 93,612,000Source | 97,739,000Source | 84,766,000Source | 68,301,000Source |
| Research and Development ExpenseUSD | — | — | 13,423,000Source | 17,722,000Source | 12,522,000Source | 18,391,000Source | 13,004,000Source | 25,378,000Source | 71,043,000Source | 76,478,000Source | 68,126,000Source | 54,077,000Source |
Offerings
Registration 333-296016
Filing attachments
d80190dex991.htm · 8-K · 2026-11-12
Exhibit 99.1 PepGen Announces Proposed $125.0 Million Public Offering of Common Stock BOSTON - November 10, 2026 - PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company pioneering oligonucleotide therapies with the potential to transform the treatment of rare genetic diseases, today announced the launch of a public offering of $125.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. …
Read attachment ↗d80190dex992.htm · 8-K · 2026-11-12
Exhibit 99.2 PepGen Announces Pricing of $125 Million Public Offering BOSTON - November 11, 2026 - PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company pioneering oligonucleotide therapies with the potential to transform the treatment of rare genetic diseases, today announced the pricing of a public offering of 25,000,000 shares of its common stock at a price to the public of $5.00 per share. The aggregate gross proceeds to PepGen from this offering are expected to be $125 millio…
Read attachment ↗pepg-ex99_1.htm · 8-K · 2026-11-10
PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights - Positive FREEDOM2-DM1 10 mg/kg cohort results demonstrated highest reported splicing correction and improvements across multiple functional measures - - 12.5 mg/kg FREEDOM2-DM1 cohort fully enrolled, with participants having received up to three doses; results expected in 1H 2027 - - FREEDOM-OLE 10 mg/kg safety and 5 mg/kg clinical data expected in January 2027 - - Well-funded with $104.8M of cash as of S…
Read attachment ↗pepg-ex99_2.htm · 8-K · 2026-11-10
PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures - Mean splicing correction of 46.5% following four monthly doses of PGN-EDODM1, five of six participants having more than 20% splicing correction and four participants exceeding 50% splicing correction - - Video Hand Opening Time (vHOT), a measure of myotonia, improved by 3.9 seconds (52.7%) from baseline at Week 16 - - Meaning…
Read attachment ↗pepg-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 pepg-ex99_1.htm EX-99.1 EX-99.1 PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg - - 10 mg/kg FREEDOM2-DM1 cohort fully enrolled, with 7 of 8 participants having completed dosing; data expected in November - - Results from 12.5 mg/kg FREEDOM2-DM1 cohort expected in 1H 2027 - - Wel…
Read attachment ↗pepg-ex99_2.htm · 8-K · 2026-08-06
EX-99.2 3 pepg-ex99_2.htm EX-99.2 August 2026 Company Presentation Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressi…
Read attachment ↗